# Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke

> **NCT02869009** · PHASE3 · COMPLETED · sponsor: **General Hospital of Shenyang Military Region** · enrollment: 3000 (actual)

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** clopidogrel
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT02869009
- **Lead sponsor:** General Hospital of Shenyang Military Region
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 3000 (ACTUAL)
- **Last updated:** 2022-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02869009

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02869009, "Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02869009. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*